多发性硬化症中的布鲁顿氨酸激酶抑制剂:证据和预期
1Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Current opinion in neurology
|March 27, 2024
概括
布鲁顿氨酸激酶 (BTK) 抑制剂通过向中枢神经系统炎症来治疗多发性硬化症 (MS) 是有前途的. 虽然一些BTK抑制剂在早期试验中显示出有效性,但后期的研究显示出混合的结果,突出了进一步研究的需要.
科学领域:
- 神经免疫学 神经免疫学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 多发性硬化症 (MS) 患者由于持续的中枢神经系统 (CNS) 炎症,尽管存在治疗方法,但经常面临残疾进展.
- 布鲁顿氨酸激酶 (BTK) 在B细胞和微质细胞功能中起着关键作用,在MS病变发生过程中至关重要.
- 透中枢神经系统的BTK抑制剂提供了一种潜在的策略,通过向跨越血脑屏障的免疫细胞来对抗多发性硬化.
研究的目的:
- 审查针对多发性硬化症 (MS) 的布鲁顿氨酸激酶 (BTK) 抑制剂的初步临床试验结果.
- 评估BTK抑制剂在治疗渐进性多发性硬化中中枢神经系统分隔性炎症方面的潜力.
主要方法:
- 对BTK抑制剂在复发性和渐进性MS中的正在进行和已完成的临床试验的审查.
- 分析2期和3期研究的疗效和安全性数据.
主要成果:
- 埃沃布鲁丁尼布,托莱布鲁丁尼布和费内布鲁丁尼布在治疗复发性多发性硬化症的第二阶段试验中显示出有效性和安全性.
- 对埃沃布鲁丁尼布和托莱布鲁丁尼布进行长达3-5年的扩展研究表明,这种疗效持续了3-5年.
- 埃沃布鲁丁尼布在减少复发率方面没有超过特里弗卢诺米德在两个复发性MS的第三阶段试验中.
结论:
- 抑制BTK是一种有希望的治疗途径,用于向MS中中枢神经系统炎症.
- 第三阶段试验结果对于了解BTK抑制剂在MS中的比较疗效和安全性至关重要.
- BTK 抑制剂可能在多发性硬化症的未来治疗环境中发挥重要作用.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:00Enzyme-linked Receptors
78.3K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.3K
01:26Receptor Tyrosine Kinases
12.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.8K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162